A study published in NEJM suggests that diabetic patients with chronic kidney disease are more likely to suffer heart complications or die if they need higher doses of Amgen's Aranesp to reach recommended treatment goals. Commenting on the data, lead researcher Scott Solomon said "it is really hard to justify this particular therapy, despite the fact that it’s still being used very heavily for people with chronic kidney disease."
Reference Articles
Heart risks rise for kidney patients on higher doses of Amgen's Aranesp - (Bloomberg)
Anemia drugs could pose threat to some kidney patients - (BusinessWeek)
Erythropoietic response and outcomes in kidney disease and type 2 diabetes - (NEJM)
**Published in "First Word"
Diario digital con noticias de actualidad relacionadas con el mundo de la salud. Novedades, encuestas, estudios, informes, entrevistas. Con un sencillo lenguaje dirigido a todo el mundo. Y algunos consejos turísticos para pasarlo bien
Traductor
Subscribe to:
Post Comments (Atom)
CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies
Copyright © Noticia de Salud
No comments:
Post a Comment